Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Avidity Biosciences (Nasdaq: RNA) has announced new equity grants under its 2022 Employment Inducement Incentive Award Plan. The company granted 263,000 non-qualified stock options and 131,450 restricted stock units (RSUs) to 33 new non-executive employees as employment inducements, complying with Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $26.66 per share, matching Avidity's closing price on Nasdaq Global Market on April 17, 2025. The options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest in four equal annual installments. Both grants require continued employment for vesting.

Positive

• Company demonstrates ability to attract new talent with 33 new hires
• Structured equity compensation plan aligns employee interests with shareholders

Negative

• Potential dilution from 263,000 new stock options and 131,450 RSUs

News Market Reaction

+3.26%

1 alert

+3.26% News Effect

On the day this news was published, RNA gained 3.26%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, April 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on April 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 263,000 shares of its common stock and 131,450 restricted stock units ("RSUs") to thirty-three (33) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Avidity, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with Avidity, pursuant to Nasdaq Listing Rule 5635(c)(4). 

The options have an exercise price of $26.66 per share, which is equal to the closing price of Avidity's common stock on The Nasdaq Global Market on April 17, 2025. The shares subject to the stock options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter, subject to each employee's continued employment with Avidity on such vesting dates. The RSUs will vest in four equal installments on the first four anniversaries of the vesting commencement date, subject to each employee's continued employment with Avidity on such vesting dates. The awards are subject to the terms and conditions of the 2022 Inducement Plan and the terms and conditions of a stock option agreement or RSU agreement, as applicable, covering the grant.

About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare neuromuscular diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In addition, Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and X.

Investor Contact:
Kat Lange
(619) 837-5014
investors@aviditybio.com

Media Contact:
(619) 837-5016
media@aviditybio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302433607.html

SOURCE Avidity Biosciences, Inc.

FAQ

What is the vesting schedule for Avidity Biosciences (RNA) stock options granted in April 2025?

The stock options vest over 4 years, with 25% vesting after the first year and the remaining 75% vesting monthly over 36 months, subject to continued employment.

How many RSUs did Avidity Biosciences (RNA) grant in its April 2025 inducement awards?

Avidity Biosciences granted 131,450 RSUs to 33 new non-executive employees.

What is the exercise price for RNA's April 2025 inducement stock options?

The stock options have an exercise price of $26.66 per share, equal to RNA's closing price on April 17, 2025.

How do the RSUs vest in Avidity's April 2025 inducement grants?

The RSUs vest in four equal annual installments over four years, subject to continued employment.